{"id":"tlc590","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1077896","moleculeType":"Small molecule","molecularWeight":"274.41"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"As a liposomal drug product developed by Taiwan Liposome Company, TLC590 encapsulates its active agent within lipid vesicles to enhance drug stability, prolong circulation time, and enable preferential accumulation at target tissues. This formulation approach typically reduces off-target toxicity while improving therapeutic efficacy compared to conventional formulations.","oneSentence":"TLC590 is a liposomal formulation designed to deliver its active pharmaceutical ingredient with improved pharmacokinetics and reduced systemic toxicity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:39:04.340Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06574269","phase":"PHASE2","title":"A Study on TLC590 for Managing Postsurgical Pain","status":"RECRUITING","sponsor":"TLC Biopharmaceuticals, Inc.","startDate":"2024-09-30","conditions":"Postsurgical Pain Management","enrollment":120},{"nctId":"NCT07222748","phase":"PHASE3","title":"A Study of TLC590 for Postsurgical Pain Following Bunionectomy","status":"RECRUITING","sponsor":"TLC Biopharmaceuticals, Inc.","startDate":"2025-11-17","conditions":"Postoperative Pain","enrollment":300},{"nctId":"NCT03754049","phase":"PHASE2","title":"A Phase 2, Open Label, Pharmacokinetic (PK) Study of TLC599 in Subjects With Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2019-01-21","conditions":"Osteoarthritis of the Knee","enrollment":102},{"nctId":"NCT05161637","phase":"PHASE2, PHASE3","title":"Phase 2/3 Study of TLC590 for Postsurgical Pain Management","status":"NOT_YET_RECRUITING","sponsor":"Taiwan Liposome Company","startDate":"2025-04","conditions":"Postsurgical Pain Management","enrollment":415},{"nctId":"NCT03591146","phase":"PHASE1, PHASE2","title":"Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2018-07-31","conditions":"Inguinal Hernia","enrollment":65},{"nctId":"NCT03838133","phase":"PHASE2","title":"A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy","status":"COMPLETED","sponsor":"Taiwan Liposome Company","startDate":"2019-03-05","conditions":"Hallux Valgus","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TLC590 (Ropivacaine Liposome Injectable Suspension)","TLC590 (Ropivacaine Extended-Release Injectable Suspension)","intestigational drug"],"phase":"phase_3","status":"active","brandName":"TLC590","genericName":"TLC590","companyName":"Taiwan Liposome Company","companyId":"taiwan-liposome-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":1},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}